following an abbreviated submission:
dasatinib (Sprycel®) is accepted for use within NHSScotland.
Indication under review: for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
SMC has previously accepted dasatinib for use in the treatment of adult patients with newly diagnosed Ph+ CML-CP (SMC No. 1170/16) and Ph+ CML-CP resistant or intolerant to prior therapy including imatinib (SMC No. 370/07).
Dasatinib was accepted for use in the treatment of adult patients with Ph+ CML-CP resistant or intolerant to prior therapy including imatinib (SMC No. 370/07) following a submission under the orphan process.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of dasatinib. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.
Download detailed advice361KB (PDF)
Medicine details
- Medicine name:
- dasatinib (Sprycel)
- SMC ID:
- SMC2142
- Indication:
- the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 April 2019